相似文献
1
Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine.
Biochem J. 1989 Sep 15;262(3):881-5. doi: 10.1042/bj2620881.
2
Importance of the intestine as a site of metformin-stimulated glucose utilization.
Br J Pharmacol. 1994 Jun;112(2):671-5. doi: 10.1111/j.1476-5381.1994.tb13128.x.
3
In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes.
Endocrinology. 1993 Jul;133(1):304-11. doi: 10.1210/endo.133.1.8391425.
4
Effects of metformin on insulin resistance after injury in the rat.
Diabetologia. 1976 Mar;12(1):53-60. doi: 10.1007/BF01221965.
5
Effect of metformin on glucose metabolism in the splanchnic bed.
Br J Pharmacol. 1992 Apr;105(4):1009-13. doi: 10.1111/j.1476-5381.1992.tb09093.x.
6
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Eur J Pharmacol. 2005 Sep 5;519(1-2):182-90. doi: 10.1016/j.ejphar.2005.05.042.
7
Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
J Pharmacol Exp Ther. 2004 Aug;310(2):614-9. doi: 10.1124/jpet.103.064964. Epub 2004 Mar 23.
8
Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin.
Biochem Pharmacol. 2006 Dec 15;72(12):1757-62. doi: 10.1016/j.bcp.2006.08.020.
9
In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats.
Endocrinology. 1983 Apr;112(4):1346-51. doi: 10.1210/endo-112-4-1346.
10
Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Eur J Pharmacol. 2009 Nov 25;623(1-3):141-7. doi: 10.1016/j.ejphar.2009.09.003. Epub 2009 Sep 15.
引用本文的文献
1
Metformin-regulated glucose flux from the circulation to the intestinal lumen.
Commun Med (Lond). 2025 Mar 3;5(1):44. doi: 10.1038/s43856-025-00755-4.
2
The gastrointestinal tract is a major source of the acute metformin-stimulated rise in GDF15.
Sci Rep. 2024 Jan 22;14(1):1899. doi: 10.1038/s41598-024-51866-2.
3
Unveiling the potential pleiotropic effects of metformin in treating COVID-19: a comprehensive review.
Front Mol Biosci. 2023 Oct 10;10:1260633. doi: 10.3389/fmolb.2023.1260633. eCollection 2023.
4
Metformin acts in the gut and induces gut-liver crosstalk.
Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2211933120. doi: 10.1073/pnas.2211933120. Epub 2023 Jan 19.
5
Development of minimally invasive C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia.
Mol Genet Metab Rep. 2022 May 11;31:100880. doi: 10.1016/j.ymgmr.2022.100880. eCollection 2022 Jun.
6
Metformin action in the gut-insight provided by [F]FDG PET imaging.
Diabetol Int. 2021 Sep 23;13(1):35-40. doi: 10.1007/s13340-021-00545-y. eCollection 2022 Jan.
7
Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells.
Sci Rep. 2021 Jan 28;11(1):2529. doi: 10.1038/s41598-021-81349-7.
8
"Treasure Your Exceptions"-Studying Human Extreme Phenotypes to Illuminate Metabolic Health and Disease: The 2019 Banting Medal for Scientific Achievement Lecture.
Diabetes. 2021 Jan;70(1):29-38. doi: 10.2337/dbi19-0037.
9
Glucose transporters in the small intestine in health and disease.
Pflugers Arch. 2020 Sep;472(9):1207-1248. doi: 10.1007/s00424-020-02439-5. Epub 2020 Aug 23.
10
Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):1543-1558. doi: 10.1161/ATVBAHA.119.313883. Epub 2020 Apr 9.
本文引用的文献
1
Enzymic determination of D(-)-beta-hydroxybutyric acid and acetoacetic acid in blood.
Biochem J. 1962 Jan;82(1):90-6. doi: 10.1042/bj0820090.
2
Tissue distribution of C14-labeled beta-phenethylbiguanide.
Diabetes. 1960 May-Jun;9:163-6. doi: 10.2337/diab.9.3.163.
3
The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects.
Diabetologia. 1980 Aug;19(2):93-6. doi: 10.1007/BF00421851.
4
Glucose turnover during pregnancy in anaesthetized post-absorptive rats.
Biochem J. 1981 May 15;196(2):633-6. doi: 10.1042/bj1960633.
5
alpha-Methylglucoside satisfies only Na+-dependent transport system of intestinal epithelium.
Am J Physiol. 1981 Nov;241(5):C227-32. doi: 10.1152/ajpcell.1981.241.5.C227.
6
[Effect of long-term metformin treatment on the development of diabetes in genetically diabetic mice (DBM) (author's transl)].
Diabete Metab. 1981 Dec;7(4):251-8.
7
Pharmacologic effects of metformin in relation to its disposition in alloxan diabetic rats.
J Pharmacobiodyn. 1983 Feb;6(2):71-87. doi: 10.1248/bpb1978.6.71.
8
Clinical diagnosis of hyperlipoproteinemia.
Am J Med. 1983 May 23;74(5A):5-9.
9
Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus.
Diabetologia. 1982 Oct;23(4):313-9. doi: 10.1007/BF00253736.
10
Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro.
Diabete Metab. 1984 Dec;10(5):311-5.
Zotero 插件